International Association for the Study of Lung Cancer

01/11/2026

Managing complex lung cancer cases requires true multidisciplinary coordination.

Join our upcoming webinar on February 26 to explore practical strategies for integrating mediastinal staging, post-operative radiotherapy, and sequencing treatment after induction chemo-immunotherapy.

Learn how to bridge practice gaps and deliver more collaborative, evidence-based care.
Register now: https://bit.ly/4bqGS9G

01/10/2026

Don’t miss the opportunity to engage with the newest advances shaping lung cancer care!

The 2026 Targeted Therapies of Lung Cancer Conference (TTLC) features sessions focused on emerging clinical evidence, innovative targeted therapies, and evolving treatment strategies.

Register today: https://www.ttlc-iaslc.org/

01/09/2026

Have you been nominated or are you thinking about nominating yourself?

There’s still time! ⏰
Self-nominations and acceptances for the IASLC Distinguished Service & Lectureship Awards are open through January 14, 2026, at 12 PM MST.

Don’t miss this opportunity to be recognized for your contributions, submit or accept a nomination today:
https://bit.ly/3YJ0QVw

01/09/2026

🌎 Now Accepting Applications – Latin America Regional Group

We are proud to announce that we are now accepting applications from qualified IASLC members in Latin America to serve on the Latin America Regional Group.

This group will help inform IASLC’s strategic membership growth and implementation framework in Latin America and identify ways to better support those involved in the thoracic malignancy community across the region.

Members of the group will:
• Collaborate with IASLC members and leadership to identify regional barriers and opportunities
• Support Latin American membership growth and engagement
• Participate in virtual and in-person meetings and group activities

Applications close February 6, 2026. Learn more: https://bit.ly/4qFOhGr

01/07/2026

🎉 We’re kicking off the new year with a brand-new podcast episode! 🎧
To start the year, we’re exploring the powerful role media plays in shaping how lung cancer is understood, from awareness to stigma and public perception.

Join us as we dive into how news, film, and storytelling influence empathy, understanding, and action.

Learn more and listen here: https://bit.ly/3L0Cnbl

01/05/2026

A new year brings new advances in lung cancer research.
The 2026 Targeted Therapies of Lung Cancer Meeting (TTLC) brings together experts to explore the latest breakthroughs in clinical research and targeted therapies, along with engaging sessions and meaningful discussion. Registration is open. We hope you'll join us! https://bit.ly/3KP8GtL

01/05/2026

Register now for the European Lung Cancer Congress 2026!
Join leading experts in thoracic oncology from around the world at ELCC 2026, taking place 25–28 March 2026 in Copenhagen, Denmark. This premier event offers cutting-edge insights into lung cancer research, prevention, early detection, diagnosis, and multidisciplinary care. Whether you’re a clinician, researcher, or healthcare professional, ELCC is your chance to learn, network, and shape the future of lung cancer care.

Learn more and register: https://bit.ly/3N0fDZq

01/03/2026

Across the globe, members of our thoracic oncology community go above and beyond leading research, mentoring colleagues, and improving patient care in every region.

The IASLC Distinguished Service and Lectureship Awards are your opportunity to recognize those making a lasting impact. Self-nomination and acceptance are still open through January 14, 2026, 12 PM MST!

✨ Distinguished Service Awards honor lifetime leaders who have shaped thoracic oncology worldwide.
✨ Lectureship Awards celebrate rising stars whose work inspires colleagues and strengthens our global community.

If you, or a colleague, have advanced research, collaboration, or patient care in meaningful ways, now is the time to ensure that work is recognized.

Complete your nomination or acceptance today: https://bit.ly/3YJ0QVw

01/02/2026

Lung cancer is a global challenge, but strategic policy change can make a real difference.

Check out the latest IASLC Spotlight featuring Dr. Gilberto de Lima Lopes, Chair of the Global Policy and Partnerships Committee, on how this expert group is working to shape evidence-based policies, foster partnerships, and advance equitable access to care around the world.

👉 Read more:

In a Q&A with ILCN, Dr. Gilberto de Lima Lopes, Committee Chair, details how the committee is working to address the most significant global challenges in lung cancer care.

01/01/2026

🎉 Celebrating 20 Years of the Journal of Thoracic Oncology (JTO)! 🎉

This milestone would not be possible without the vision and dedication of our past editors, reviewers, and contributors who recognized the need for a journal devoted to advancing research in thoracic malignancies. We are deeply grateful for their leadership and commitment.

As we celebrate 20 years of JTO, we’re excited to mark the occasion throughout the year with highlights from past editors, fun facts, inspiring videos, special anniversary articles, and upcoming events. Be sure to follow our social media channels, including Thoracic Circle, to join the celebration.

We also extend our sincere thanks to our current editorial leadership and team for their continued excellence and stewardship of the journal.

12/31/2025

This year, the FDA approved several new therapies that are changing what’s possible for people living with lung cancer: 🧬 Datopotamab deruxtecan – EGFR-mutated NSCLC 🧬 Sunvozertinib – EGFR ins 20 mutated NSCLC 🧬 Sevabertinib – HER2-mutated NSCLC 🧬 Zongertinib – HER2-mutated NSCLC 🧬 Tarlatamab – advanced small cell lung cancer (full approval) Each approval represents progress toward more personalized, effective care and renewed hope for patients and families worldwide as regulatory approvals of these agents are under review in several countries.

SCLC

12/31/2025

Dr. Lawson Eng and team used the IASLC 9th Edition Staging Database to argue for non-anatomical factors in lung cancer staging—pushing the field toward more precise, personalized prognosis.

👉 More in ILCN:

Using the IASLC 9th Edition Staging Database, Dr. Lawson Eng and colleagues evaluated the association between smoking status at diagnosis and OS.